Humaniqe Biopharmaceuticals Private Limited Pharmaceutical Export Profile — India (DGFT 2022–2026)

Name: Humaniqe Biopharmaceuticals Private Limited Pharmaceutical Export Portfolio Dataset — 2 Products, $158.6K FOB USD, India (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Humaniqe Biopharmaceuticals Private Limited — Pharmaceutical Exporter Profile (2026) | 2 Products, $158.6K Trade | TransData Nexus

Humaniqe Biopharmaceuticals Private Limited

Indian Pharmaceutical Exporter · Analgesics & Antipyretics Specialist · $158.6K Total Trade · DGFT Verified

Humaniqe Biopharmaceuticals Private Limited is an Indian pharmaceutical exporter with a total trade value of $158.6K across 2 products in 2 therapeutic categories. Based on 7 verified export shipments from Indian Customs (DGFT) records, the company actively competes across multiple product segments. Top exports include Morphine ($103.6K), Daratumumab ($55.1K), .

Humaniqe Biopharmaceuticals Private Limited — Export Portfolio & Destination Treemap

Humaniqe Biopharmaceuticals Private Limited pharmaceutical export portfolio — 2 products across 2 therapeutic categories. Source: Indian Customs (DGFT).

Who is Humaniqe Biopharmaceuticals Private Limited? — Company Overview & Market Position

Humaniqe Biopharmaceuticals Private Limited is a privately held pharmaceutical company established on September 6, 2019, in Visakhapatnam, Andhra Pradesh, India. The company is registered under the Corporate Identification Number (CIN) U52100AP2019PTC112835 and operates as a non-government entity. Its authorized capital is ₹2.5 million, with a paid-up capital of ₹1.1 million. The registered office is located at Door No. 14-37-38/5, SF-302, 3rd Floor, MVV Neeladri Maharanipeta, Visakhapatnam, Andhra Pradesh, 530002.

The company is unlisted and has maintained an active status since its incorporation. As of the latest available data, the directors are Modalavalasa Sireesha and Singuru Neelima, both appointed on September 6, 2019. The most recent Annual General Meeting (AGM) was held on September 28, 2024, with the balance sheet filed on March 31, 2024.

What Does Humaniqe Biopharmaceuticals Private Limited Export? — Product Portfolio Analysis

Top Products by Export Value

1Morphine$103.6K 2

Product Portfolio — Top 2 by Export Value

Humaniqe Biopharmaceuticals Private Limited exports 2 pharmaceutical products across 2 therapeutic categories.

#	Product	Category	Export Value	Shipments	Market Share	Rank
1	Morphine	Analgesics & Antipyretics	$103.6K	4	0.6%	9
2	Daratumumab	Advanced Oncology	$55.1K	3	4.1%	7

Humaniqe Biopharmaceuticals Private Limited exports 2 pharmaceutical products across 2 therapeutic categories with a total export value of $158.6K. The top category is Analgesics & Antipyretics (65.3% of portfolio), followed by Advanced Oncology (34.7%), indicating a concentrated portfolio with the top 5 products accounting for 100.0% of total export value.

Humaniqe Biopharmaceuticals Private Limited — Corporate Profile & Information

Headquarters, ownership, manufacturing facilities, and key leadership

1Corporate Overview

2Manufacturing Facilities

Specific details regarding Humaniqe Biopharmaceuticals' manufacturing facilities, including locations, capacities, and specializations, are not publicly disclosed. The company's export data indicates a focus on finished pharmaceutical formulations, such as tablets, capsules, syrups, and injections, rather than raw active pharmaceutical ingredients (APIs) or bulk drugs. This suggests that the manufacturing operations are likely geared towards the production of these finished dosage forms.

3Key Leadership

The key leadership of Humaniqe Biopharmaceuticals Private Limited comprises:

Modalavalasa Sireesha: Director, appointed on September 6, 2019.

Singuru Neelima: Director, appointed on September 6, 2019.

There is no publicly available information regarding other executive roles such as CEO, CFO, or additional key executives within the company.

TransData Nexus Research · Government registries, company filings, regulatory databasesMar 2026

Where Does Humaniqe Biopharmaceuticals Private Limited Export? — Destination Intelligence

Regulated market presence, emerging market penetration, and geographic strategy

1Regulated Markets

Humaniqe Biopharmaceuticals Private Limited's export data indicates shipments of finished pharmaceutical formulations, including morphine and daratumumab, across two therapeutic categories: Analgesics & Antipyretics and Advanced Oncology. However, specific details regarding regulatory filings, approvals, and market access status in the United States, European Union, United Kingdom, Australia, and Japan are not publicly available. The company's focus on finished formulations suggests that it may be targeting markets with established regulatory pathways for such products.

2Emerging Markets

The company's export data does not provide specific information about its presence in emerging markets such as Africa, Latin America, or Southeast Asia. The export of products like morphine and daratumumab indicates a focus on specialized pharmaceutical markets, which may include emerging economies with growing healthcare needs. However, without explicit data on WHO prequalification or other certifications, it is challenging to assess the company's penetration in these regions.

3Geographic Strategy

Humaniqe Biopharmaceuticals Private Limited — Manufacturing & Regulatory Profile

FDA status, WHO-GMP certification, EU GMP compliance, and regulatory track record

1FDA Status

There is no publicly available information regarding Humaniqe Biopharmaceuticals Private Limited's FDA facility registrations, approved Abbreviated New Drug Applications (ANDAs), Drug Master File (DMF) filings, or inspection history. The company's export data indicates shipments of finished pharmaceutical formulations, but without explicit FDA approvals or registrations, it is unclear whether these products are authorized for sale in the U.S. market.

2WHO & EU GMP

The export data does not provide information on whether Humaniqe Biopharmaceuticals Private Limited holds WHO prequalification or EU Good Manufacturing Practice (GMP) certificates. These certifications are crucial for market access in various international regions. The absence of such certifications may limit the company's ability to enter or expand in certain markets that require adherence to these standards.

3CDSCO & Indian Regulatory

Specific details regarding Humaniqe Biopharmaceuticals Private Limited's manufacturing licenses from the Central Drugs Standard Control Organisation (CDSCO), approvals from state drug controllers, or export No Objection Certificates (NOCs) are not publicly available. The company's export data indicates a focus on finished pharmaceutical formulations, suggesting compliance with relevant Indian regulatory requirements for such products.

Humaniqe Biopharmaceuticals Private Limited — Competitive Positioning Among Indian Pharma Exporters

Market share comparison, key differentiators, and strategic analysis

1Competitive Landscape

Humaniqe Biopharmaceuticals Private Limited operates in the pharmaceutical export sector, focusing on finished formulations in therapeutic areas such as Analgesics & Antipyretics and Advanced Oncology. The company's export data indicates shipments of morphine and daratumumab, which are specialized products with specific market dynamics. Without detailed information on competitors in these therapeutic categories, it is challenging to provide a comprehensive market share comparison or head-to-head analysis.

2Key Differentiators

Humaniqe Biopharmaceuticals Private Limited's focus on finished pharmaceutical formulations, particularly in specialized therapeutic areas like Analgesics & Antipyretics and Advanced Oncology, may serve as a key differentiator. This specialization suggests a strategic emphasis on high-demand, niche markets, potentially allowing the company to leverage expertise and establish a strong market presence in these segments.

3Strategic Position

The company's export data indicates a concentrated product portfolio, with shipments of two products across two therapeutic categories. This suggests a strategic focus on specific therapeutic areas, potentially to leverage expertise and market demand. The lack of diversification in product offerings may expose the company to risks associated with market fluctuations in these therapeutic segments. Future strategic directions may involve expanding the product portfolio or entering new therapeutic areas to mitigate such risks.

Buyer Due Diligence Brief — Evaluating Humaniqe Biopharmaceuticals Private Limited as a Supplier

Track record assessment, certifications to verify, and pre-order checks

1Supplier Assessment

Humaniqe Biopharmaceuticals Private Limited's export data indicates shipments of finished pharmaceutical formulations, including morphine and daratumumab, across two therapeutic categories. The company's focus on specialized products suggests a commitment to quality and compliance with international standards. However, without detailed information on manufacturing practices, certifications, and regulatory approvals, it is challenging to fully assess the company's track record, export volume consistency, and reliability.

2Certifications to Verify

Importers should verify the following certifications when considering products from Humaniqe Biopharmaceuticals Private Limited:

FDA Approval: Confirm that the products are approved by the U.S. Food and Drug Administration (FDA) for sale in the U.S. market. Verification can be done through the FDA's official website or by contacting the company directly.

WHO-GMP Certification: Ensure that the manufacturing facilities comply with the World Health Organization's Good Manufacturing Practice standards. This can be verified by checking the WHO's official prequalification list or by requesting certification details from the company.

Frequently Asked Questions — Humaniqe Biopharmaceuticals Private Limited

How many pharmaceutical products does Humaniqe Biopharmaceuticals Private Limited export from India?

Humaniqe Biopharmaceuticals Private Limited exports 2 pharmaceutical products across 2 therapeutic categories. The top exports are Morphine ($103.6K), Daratumumab ($55.1K). Total export value is $158.6K.

What is Humaniqe Biopharmaceuticals Private Limited's total pharmaceutical export value?

Humaniqe Biopharmaceuticals Private Limited's total pharmaceutical export value is $158.6K, based on 7 verified shipments recorded in Indian Customs (DGFT) data.

What therapeutic categories does Humaniqe Biopharmaceuticals Private Limited cover?

Humaniqe Biopharmaceuticals Private Limited exports across 2 therapeutic categories. The largest are Analgesics & Antipyretics (65.3%, 1 products), Advanced Oncology (34.7%, 1 products).

Get Full Humaniqe Biopharmaceuticals Private Limited Export Intelligence

Access shipment-level details, pricing data, buyer connections, product breakdown, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify manufacturer licensing, GMP certification, and export registration with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports per product category. For current shipment-level data, contact TransData Nexus.